Related Experiment Video
Updated: Jul 16, 2026
Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
Translational considerations for CNS gene therapy
Deborah A Ryan1, Howard J Federoff
1University of Rochester School of Medicine & Dentistry, Interdepartmental Graduate Program in Neuroscience, Rochester, New York, USA.
Abstract:
Gene transfer is being rigorously evaluated in the laboratory in the preparation for the development of clinical therapies. Many CNS diseases, which have proved more challenging to treat than peripheral disorders, are prime candidates for gene therapy. However, there are numerous considerations in the development of gene therapy, including delivery, maintenance of expression, transgene level regulation, toxicity of the viral vector system and safety of the gene product. The authors review these issues and discuss various approaches used in preclinical studies. Alzheimer's and Parkinson's disease are employed as models, in which much research has already been performed, to address disease-specific questions about gene therapy approaches.
Insights
Gene therapy shows promise for challenging central nervous system (CNS) diseases. Preclinical studies explore delivery, safety, and regulation for conditions like Alzheimer's and Parkinson's disease.
Area of Science:
- Neuroscience
- Molecular Biology
- Biotechnology
Background:
- Central nervous system (CNS) diseases present significant therapeutic challenges.
- Gene transfer is a promising approach for treating these disorders.
- Preclinical research is essential for developing safe and effective gene therapies.
Purpose of the Study:
- To review key considerations in developing gene therapy for CNS diseases.
- To discuss various preclinical approaches for gene transfer.
- To examine gene therapy strategies using Alzheimer's and Parkinson's disease models.
Main Methods:
- Review of existing literature on gene transfer for CNS disorders.
- Analysis of preclinical studies focusing on delivery and safety.
- Case studies of Alzheimer's and Parkinson's disease gene therapy models.
Main Results:
- Gene therapy development requires careful attention to delivery, expression, regulation, and safety.
- Viral vector systems and gene products necessitate thorough toxicity and safety evaluations.
- Preclinical models like Alzheimer's and Parkinson's disease are crucial for addressing disease-specific challenges.
Conclusions:
- Gene therapy holds significant potential for treating debilitating CNS diseases.
- Addressing challenges in delivery, expression, and safety is critical for clinical translation.
- Further preclinical research is vital for advancing gene therapy applications in neurology.
Related Concept Videos
00:59Gene Therapy
01:29Microorganisms in Medicine and Therapeutics